PTC THERAPEUTICS, INC.
- WARREN, NJ 07059
- ptcbio.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM expiring
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
SAM.gov registration expires in 24 days
PTC THERAPEUTICS, INC.’s registration expires on Dec 8, 2026. Renewal can take weeks; confirm it stays active through proposal submission and award.
View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI
About PTC THERAPEUTICS, INC.
- Headquarters
- WARREN, NJ 07059
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEILH7QEHP9V7W1
- CAGE1XUQ0
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 16 awards
- Total awarded
- $6,233,781
- By phase
- SBIR Phase I: 8
- SBIR Phase II: 3
- STTR Phase I: 3
- STTR Phase II: 2
- By agency
- Department of Health and Human Services: 16
- By year
- 2006: 2
- 2005: 3
- 2004: 4
- 2003: 4
- 2002: 1
- 2001: 1
- 2000: 1
Awards (most recent first)
Mechanism of nonsense mutation suppression therapy
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2006 · $808,539
Solicitation PHS2006-2 (2006)
Mechanism of nonsense mutation suppression therapy
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2006 · $808,539
Research partner: University of Massachusetts Medical School
A Novel HIV-1 Latency System for Drug Discovery
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2005 · $100,000
Solicitation PHS2005-2 (2005)
A Novel HIV-1 Latency System for Drug Discovery
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2005 · $100,000
Research partner: UNIV OF MEDICINE & DENTISTRY OF NEW JERSEY
Development of an inhibitor of VEGF expression
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2005 · $1,459,580
Solicitation PHS2005-2 (2005)
Mechanism of nonsense mutation suppression therapy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $100,945
Solicitation PHS2004-2 (2004)
Mechanism of nonsense mutation suppression therapy
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $100,945
Research partner: UNIV OF MASSACHUSETTS MED SCH WORCESTER
Novel Approaches to Identify Anti-Angiogenesis Drugs
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $188,172
Solicitation PHS2004-2 (2004)
Developing antiviral agents that inhibit HCV translation
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2004 · $1,125,290
Solicitation PHS2004-2 (2004)
Targeting RNA to develop novel antibacterial agents
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2003 · $152,325
Developing antiviral agents that inhibit HCV translation
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2003 · $152,326
Novel thereapeutics to treat genetic disorders
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2003 · $172,530
A virus/cell based assay for discovery of anti-HIV drugs
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2003 · $558,030
Research partner: UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
A VIRUS/CELL BASED ASSAY FOR DISCOVERY OF ANTI-HIV DRUGS
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2002 · $126,560
Research partner: UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY
Novel targets for HIV-1: Tat-TAR interactions
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2001 · $140,000
Not Available
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2000 · $140,000
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
No active exclusion on record (checked Nov 14, 2026).
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · as of Nov 14, 2026
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 325412Pharmaceutical Preparation ManufacturingPrimary
- 325414Biological Product (except Diagnostic) Manufacturing
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with PTC THERAPEUTICS, INC.?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.